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1021-101 Association of Glomerular Filtration Rate on 
Presentation With Subsequent Mortality in Non- ST 
Elevation Acute Coronary Syndromes
Raphaelle Dumaine, C Michael Gibson, Duane S. Pinto, Sabina A. Murphy, David A. 
Morrow, Hans-Peter Hobbach, Stephen D. Wiviott, Christopher P. Cannon, Elliott M. 
Antman, Eugene Braunwald, TIMI Study Group, Boston, MA
Background: Renal function impairment is associated with poor prognosis in the setting
of ST-elevation myocardial infarction.
Methods: We hypothesized that decreased glomerular filtration rate (GFR) was associ-
ated with poor short- and long-term prognosis in patients with non ST-elevation acute
coronary syndromes (NSTE-ACS). Data were pooled from NSTE-ACS TIMI trials, and
patients were divided in 3 groups: with normal (>=90 mL/min/1.73m2,group 1, n=4952),
mildly decreased (60-89 mL/min/1.73m2, group 2, n=6262) and moderately to severely
decreased GFR (<60 mL/min/1.73m2, group 3, n=2093) on presentation.
Results: Mortality increased stepwise with decreasing GFR: 1.27%, 2.11%, and 5.02%
at 30 days and 2.47%, 3.79% and 9.53% at 6 months in groups 1, 2, and 3 respectively
(p<0.0001 for both). The combination of TIMI risk score (TRS) tertiles and decreasing
tertiles of GFR provided further mortality stratification with highest 6-month mortality rate
(15.44%) in lowest GFR combined with highest TRS (figure). Furthermore, decreased
GFR was associated with mortality independent of TRS (at 30 days, OR=1.41 in group 2,
p=0.03; OR=3.11 in group 3, p<0.001). In addition, stroke incidence at 30-day increased
with decreased GFR: 0.33%, 0.59% and 1.27 % in groups 1, 2, and 3 respectively
(p<0.0001).
Conclusion: In the setting of NSTE-ACS, impaired GFR is associated with increased 30-
day and 6-month mortality independent of TRS, and is associated with increased stroke
incidence at 30 days.
1021-102 Underachievement of Low-Density Lipoprotein 
Cholesterol Goal in Patients on Statins in Clinical 
Practice: Are We Using Low Doses of Statins Too 
Often?
Alexandria J.M. Braganza, Gemma Eminowicz, Sabina A. Murphy, Peter M. DiBattiste, 
Gregory C. Flaker, Christopher P. Cannon, Brigham and Women's Hospital, Boston, MA
Background:Although clinical trials have found significant reductions in cardiovascular
events when using fixed doses of statins (e.g. 40 mg of simvastatin or pravastatin), in
clinical practice, treatment is usually initiated at lower doses. It is not clear, however, if in
clinical practice, the doses are titrated upward after the initial dose.
Methods: Among 2220 patients with non-ST elevation acute coronary syndromes, we
examined the statin doses used in those receiving statins at the time of entry in the TAC-
TICS-TIMI 18 trial, and their relationship to the measured low-density lipoprotein choles-
terol (LDL-C) on admission.
Results: At study entry, 722 (33%) patients were on statins, of whom 372 had LDL-C
measurements available: 132 (35%) were on atorvastatin, 126 (34%) on simvastatin, 58
(16%) on pravastatin, and 15% on other statins. The doses used are shown in the Figure.
Only 17% and 36% of patients were treated with the 40 mg doses of pravastatin or simv-
astatin as used in clinical trials. Only 1% of patients were treated with 80mg atorvastatin.
At entry, only 47% of these patients had LDL-C <100 mg/dl. At 6 months, although more
patients (1129, 51%) were on statins, the doses of statins used were not higher than
those used at baseline.
Conclusion: With the large number of patients on low doses of statins, and the majority
not being at LDL-C goal, our data suggest that, in addition to previously documented
underutilization of statins in clinical practice, there is also under-dosing of this important
class of drugs.
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1022-79 Is Early Prehospital Administration of Abciximab 
Superior to Periprocedural Therapy in Patients With ST-
Segment Elevation Myocardial Infarction and Planned 
Percutaneous Coronary Intervention? Early and Late 
Results From the Randomized REOMOBILE Pilot Study
Hans-Richard Arntz, Joachim Schröder, Klaus Pels, Bernhard Witzenbichler, Peter 
Schwimmbeck, Dirk Müller, Heinz-Peter Schultheiss, Benjamin Franklin Medical Center, 
Berlin, Germany
Background: Pre-treatment of pts with STEMI with abciximab already in the mobile inten-
sive care unit (MICU) is believed to facilitate percutaneous coronary intervention (PCI)
and improve outcome.
Methods: We randomised 100 pts with STEMI (age <80 yrs, symptoms <6hrs) to receive
weight adjusted abciximab at the scene (PTx, n=52) or at intervention in the cath lab
(HTx, n=48). All pts received 500 mg aspirin and 70 U/kg heparin in the MICU.
Results: Groups were balanced for sex (19% female), age (median 63 yrs), localisation of
MI (39% anterior) and symptom duration to arrival of MICU (median 50 min). Median
duration of symptoms until abciximab injection was 68 min in pts with PTx and 164 min
with HTx. Symptom duration to 1st visualisation of infarct related artery was 142 min in
pts with PTx and 152 min with HTx respectively. ST segment resolution after 60-90 min
(before PCI with PTx) was < 30% in 39%, 30-70% in 37% and >70% in 24% of pts, com-
pared to 56%, 14%, and 30% with HTx respectively. With PTx initial TIMI-flow 0/1 was
present in 48%, and TIMI-flow 2/3 in 52%, compared to 52% and 48% with HTx respec-
tively. Blush grade before intervention with PTx was 0/1 in 63%, and 2/3 in 37%, com-
pared to 66% and 34% with HTx respectively. Stents were successfully placed in 93% of
pts. TIMI-flow 3 was achieved in 88% of pts with PTx and 82% with HTx. None of the dif-
ferences were significant. Results tended to be in favour of PTx in pts who were treated
within the 1st hour after symptom onset independent of the time interval between start of
treatment and 1st visualisation of IRA. One HTx-pt died on day 4 after prolonged resusci-
tation, two pts had major bleeds (1 PTx, 1HTx). Urgent CABG was performed in 7 pts (4
PTx, 3 HTx) until day 5. Until day 180, three pts with PTx had reinfarctions, two within 30
days, one during month 4. Ten pts had ischemia driven re-PCI of IRA (5 PTx, 5 HTx),
three of these within the first 30 days after the index event.
Conclusion: Pre-hospital application of abciximab is safe and feasible. However, in some
contrast to previous reports we found only minor advantages of abciximab pre-treatment
in pts with STEMI and planned PCI. Also fast-track pre-hospital procedures in general
may have added essentially to the excellent outcome of the pts.
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